NOK 52.8
Key Takeaways
Risk factor
Poor trading liquidity
Profitability factor
Very favourable analyst view
About
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI
Target Price
The average target price of PHO.OL is 81 and suggests 52% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
